Bioxytran, Inc.
BIXT
Rank in Stocks
#31994
Bioxytran, Inc. is a pharmaceutical firm operating in the clinical development... Bioxytran, Inc. is a pharmaceutical firm operating in the clinical development phase, dedicated to creating, producing, and marketing medicinal treatments for oxygen deficiency (hypoxia) in people. Its primary drug under development, BXT-25, is a small, oxygen-transporting molecule crafted from bovine hemoglobin, stabilized by a co-polymer. This compound is intended for tackling oxygen deprivation in the brain caused by strokes, as well as addressing wound hypoxia to avert tissue death and encourage recovery. Additionally, Bioxytran is advancing ProLectin-Rx, a pectin-derived polysaccharide. This substance functions by attaching to and inhibiting galectin-1, a specific galectin, to treat mild to moderate instances of Covid-19. Established in 2008, the company maintains its main office in Newton, Massachusetts.
Share Price
$0.022425
Last synced: 2026-11-09
Market Cap
$2.22M
Change (1 day)
-2.92%
Change (1 year)
-67.92%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Bioxytran, Inc. (BIXT)
Category
Healthcare
Operating Margin for Bioxytran, Inc. (BIXT)
Operating Margin as of November 2026 TTM: 0.00%
According to Bioxytran, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Bioxytran, Inc. from 2008 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | -100.00% |
| 2017 | -162.55% | -40.31% |
| 2016 | -272.33% | -66.70% |
| 2015 | -817.88% | 76.01% |
| 2014 | -464.67% | -1.69% |
| 2013 | -472.64% | -35.41% |
| 2012 | -731.76% | -76.28% |
| 2011 | -3,085.42% | 51.27% |
| 2010 | -2,039.63% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Bioxytran, Inc.'s operating margin
What was Bioxytran, Inc.'s operating margin in 2025?
In 2025, Bioxytran, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Bioxytran, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Bioxytran, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2025 (0.00%).
How does Bioxytran, Inc.'s operating margin compare with similar companies?
Bioxytran, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.